


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

1. – 96. (cancelled)







97. (new) A pharmaceutical or cosmetic composition comprising at least one of a pharmaceutically or cosmetically acceptable carrier and a pharmaceutically or cosmetically acceptable adjuvant and at least one active ingredient selected from compounds of formula A1, including tautomers, stereoisomers thereof, pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:










wherein

- Y represents O, S or NR₄;
- R₁, R₂, R₃ and R₄ are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula A1 via a C atom or a heteroatom.

98. (new) The composition of claim 97, wherein the composition comprises at least one active ingredient selected from compounds of the following formulae, including tautomers, stereoisomers thereof, pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

A1.001	
A1.002	
A1.003	
A1.004	
A1.005	
A1.006	

A1.007	
A1.008	
A1.009	
A1.010	
A1.011	
A1.012	
A1.013	

A1.014	
A1.015	

99. (new) A method of inhibiting an activity of at least one enzyme selected from alanyl aminopeptidases and analogous enzymes in a subject in need thereof, wherein the method comprises administering to the subject at least one of the composition of claim 97 and an active ingredient thereof, alone or in combination with one or more inhibitors of dipeptidyl peptidase IV or analogous enzymes.

100. (new) A method of inhibiting an activity of at least one enzyme selected from alanyl aminopeptidases and analogous enzymes in a subject in need thereof, wherein the method comprises administering to the subject at least one of the composition of claim 98 and an active ingredient thereof, alone or in combination with one or more inhibitors of dipeptidyl peptidase IV or analogous enzymes.

101. (new) A method of topically influencing an activity of at least one enzyme selected from alanyl aminopeptidases and analogous enzymes in a subject in need thereof, wherein the method comprises topically administering to the subject at least one

of the composition of claim 97 and an active ingredient thereof, alone or in combination with one or more inhibitors of dipeptidyl peptidase IV or analogous enzymes.

102. (new) A method of topically influencing an activity of at least one enzyme selected from alanyl aminopeptidases and analogous enzymes in a subject in need thereof, wherein the method comprises topically administering to the subject at least one of the composition of claim 98 and an active ingredient thereof, alone or in combination with one or more inhibitors of dipeptidyl peptidase IV or analogous enzymes.

103. (new) A method of preventing or treating at least one condition selected from multiple sclerosis, Morbus Crohn, Colitis ulcerosa and other autoimmune diseases; inflammatory diseases; allergic asthma bronchiale and other allergic diseases; rejection of transplanted tissues and cells; skin and mucosa diseases such as psoriasis and acne; dermatological diseases associated with a hyperproliferation and changed differentiation states of fibroblasts, preferably of benign fibrosing and sclerosing skin diseases and malign fibroblastic hyperproliferation states; acute neuronal diseases, in particular ischemia-caused cerebral damage after an ischemic or hemorrhagic stroke, cranio-cerebral trauma, cardiac arrest, myocardial infarction or as a consequence of heart surgery; chronic neuronal diseases, in particular Morbus Alzheimer, Pick's disease, Progressive Supranuclear Palsy, corticobasal degeneration, frontotemporal dementia, Morbus Parkinson, in particular Morbus Parkinson coupled to chromosome 17, Morbus Huntington, prion-caused diseases and amyotrophic lateral sclerosis; chronic obstructive pulmonal disease (COPD); prostata carcinoma and other tumors as well as metastases;

Heavy Acute Respiratory Syndrome (SARS); and sepsis and sepsis-like conditions in a subject in need thereof, wherein the method comprises administering to the subject at least one of the composition of claim 97 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

104. (new) A method of preventing or treating at least one condition selected from multiple sclerosis, Morbus Crohn, Colitis ulcerosa and other autoimmune diseases; inflammatory diseases; allergic asthma bronchiale and other allergic diseases; rejection of transplanted tissues and cells; skin and mucosa diseases such as psoriasis and acne; dermatological diseases associated with a hyperproliferation and changed differentiation states of fibroblasts, preferably of benign fibrosing and sclerosing skin diseases and malign fibroblastar hyperproliferation states; acute neuronal diseases, in particular ischemia-caused cerebral damage after an ischemic or hemorrhagic stroke, cranio-cerebral trauma, cardiac arrest, myocardial infarction or as a consequence of heart surgery; chronic neuronal diseases, in particular Morbus Alzheimer, Pick's disease, Progressive Supranuclear Palsy, corticobasal degeneration, frontotemporal dementia, Morbus Parkinson, in particular Morbus Parkinson coupled to chromosome 17, Morbus Huntington, prion-caused diseases and amyotrophic lateral sclerosis; chronic obstructive pulmonal disease (COPD); prostata carcinoma and other tumors as well as metastases; Heavy Acute Respiratory Syndrome (SARS); and sepsis and sepsis-like conditions in a subject in need thereof, wherein the method comprises administering to the subject at least one of the composition of claim 98 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

105. (new) A method of preventing or treating at least one condition selected from atherosclerosis, arterial inflammation, reperfusion syndrome and stent restenosis, for example after a percutaneous transluminal angioplasty, in a subject in need thereof, wherein the method comprises administering to the subject at least one of the composition of claim 97 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

106. (new) The method of claim 105, wherein the method comprises administering at least one of the composition and an active ingredient thereof by using a stent which is coated with the at least one of the composition and an active ingredient thereof.

107. (new) A stent which is coated with at least one of the composition of claim 97 and an active ingredient thereof.

108. (new) A method of preventing or treating at least one condition selected from atherosclerosis, arterial inflammation, reperfusion syndrome and stent restenosis, for example after a percutaneous transluminal angioplasty, in a subject in need thereof, wherein the method comprises administering to the subject at least one of the composition of claim 98 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

109. (new) The method of claim 108, wherein the method comprises administering at least one of the composition and an active ingredient thereof by using a stent which is coated with the at least one of a composition and an active ingredient thereof.

110. (new) A stent which is coated with at least one of the composition of claim 98 and an active ingredient thereof.

111. (new) A method of preventing or treating an inflammation reaction at, or caused by, a medical device implanted into an organism, wherein the method comprises administering to the organism at least one of the composition of claim 97 and an active ingredient thereof in an amount sufficient for preventing or treating the inflammation reaction.

112. (new) The method of claim 111, wherein the method comprises administering at least one of the composition and an active ingredient thereof at least one of as a coating or layer on the medical device and incorporated in the medical device.

113. (new) The method of claim 111, wherein the method comprises administering at least one of the composition and an active ingredient thereof by at least one of a local and a systemic administration successively or concurrently.

114. (new) A method of preventing or treating an inflammation reaction at, or caused by, a medical device implanted into an organism, wherein the method comprises

administering to the organism at least one of the composition of claim 98 and an active ingredient thereof in an amount sufficient for preventing or treating the inflammation reaction.

115. (new) The method of claim 114, wherein the method comprises administering at least one of the composition and an active ingredient thereof at least one of as a coating or layer on the medical device and incorporated in the medical device.

116. (new) The method of claim 114, wherein the method comprises administering at least one of the composition and an active ingredient thereof by at least one of a local and a systemic administration successively or concurrently.